Drug Discovery & Pharmaceuticals

RSS

Bioactive compounds in a marine sponge show potential to kill antibiotic-resistant bacteria

A research group led by scientists at the University of São Paulo (USP) in São Carlos, Brazil, has identified a number of bioactive compounds in a marine sponge collected on Fernando de Noronha, an archipelago about 400 km off the coast of Brazil's Northeast region.

13 Jul 2022

New approach could pave the way for development of pan-coronavirus antivirals

To put the COVID-19 pandemic in the rearview mirror and prevent other coronaviruses from causing havoc, the world needs an arsenal of measures to prevent and treat these infections.

13 Jul 2022

Study suggests ZCB11 as a promising antibody drug against all SARS-CoV-2 variants of concern

Researchers at the AIDS Institute, The University of Hong Kong, Department of Microbiology, School of Clinical Medicine, the LKS Faculty of Medicine of The University of Hong Kong and the State Key Laboratory of Emerging Infectious Diseases, HKU, together with structural biologists at The Hong Kong University of Science and Technology, have demonstrated that ZCB11, a broadly neutralizing antibody derived from a local mRNA-vaccinee against the spreading Omicron variants of SARS-CoV-2, displays potent antiviral activities against all variants of concern (VOCs), including the dominantly spreading Omicron BA.1, BA1.1 and BA.2.

13 Jul 2022

Production of anti-SARS-CoV-2 antibodies from hyperimmunized chickens

A new study reports the production of neutralizing antibodies against SARS-CoV-2 in hyperimmunized hens.

12 Jul 2022

Novel COVID-19 antibody delivery approach advances to clinical trials

Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.

7 Jul 2022

New biosensor system derived from E. coli bacteria could accelerate drug development

For more affordable, sustainable drug options than we have today, the medication we take to treat high blood pressure, pain or memory loss may one day come from engineered bacteria, cultured in a vat like yogurt.

7 Jul 2022

DZNE and Intravacc receive € 2.5 million EU funding to develop a prototype ALS vaccine

DZNE and Intravacc B.V., a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines, have been awarded a funding of € 2.5 million from the European Union (EIC Transition Grant) to further develop a prototype ALS vaccine, including process development, scale-up, and toxicology study.

6 Jul 2022

BICO; Combining Life Sciences Solutions to Further Human Health

As part of our SLAS Europe 2022 coverage, we speak to Héctor Martínez, CTO of BICO, about the technology and services they offer within life sciences research.

From Society for Laboratory Automation and Screening (SLAS) 5 Jul 2022

Generation of live attenuated influenza A virus vaccine using PROTAC technology

A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines.

4 Jul 2022

Combining AI and Zebrafish to Accelerate Drug Discovery

As part of our SLAS Europe 2022 coverage, we speak to Dr. Javier Terriente, Co-founder and Chief of Drug Development at ZeClinics, about how zebrafish could be the future for discovering new therapeutics.

From Society for Laboratory Automation and Screening (SLAS) 1 Jul 2022

Anticancer drug candidate that targets a human protein could be a pan-viral medication

More than two years into the COVID-19 pandemic, people are realizing that the "new normal" will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies.

29 Jun 2022

Just like magic; automated solutions for NGS library preparation

As part of our SLAS Europe 2022 coverage, we speak to Ian Shuttler from Tecan about their new MagicPrepTM NGS technology.

From Tecan 29 Jun 2022

Investigating the prerequisites for developing RNA-based antibiotics

In the fight against the Covid-19 pandemic, mRNA-based vaccines have impressively demonstrated their potential. Using this technology, scientists were able to rapidly develop and bring to market vaccines against SARS-CoV-2 that have been extremely effective at protecting millions of people against severe disease progression of COVID-19 or even death.

29 Jun 2022

New machine learning method may improve the identification of genes that cause diseases

A new machine learning method to model gene expression levels might improve the identification of genes that cause human diseases, according to a new study by Penn State College of Medicine researchers.

28 Jun 2022

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

Natural compounds often have promising therapeutic potential but their use to treat diseases is hampered due to toxicity or non-desirable effects.

27 Jun 2022

Scientists create new fluorophores that could help fight cancer

Scientists from the Ural Federal University and the Ural Branch of the Russian Academy of Sciences have created new fluorescent chemical compounds (fluorophores) for photodynamic therapy of cancerous tumors, the latest method of treating cancer.

27 Jun 2022

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a low-dose, oral COVID antiviral drug that can be administered at home.

27 Jun 2022

Bisphosphonates appear to improve COVID-19 exposure outcomes

A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

27 Jun 2022

Drug Discovery & Pharmaceuticals

Bioactive compounds in a marine sponge show potential to kill antibiotic-resistant bacteria

New approach could pave the way for development of pan-coronavirus antivirals

Study suggests ZCB11 as a promising antibody drug against all SARS-CoV-2 variants of concern

Production of anti-SARS-CoV-2 antibodies from hyperimmunized chickens

Novel COVID-19 antibody delivery approach advances to clinical trials

New biosensor system derived from E. coli bacteria could accelerate drug development

DZNE and Intravacc receive € 2.5 million EU funding to develop a prototype ALS vaccine

BICO; Combining Life Sciences Solutions to Further Human Health

Generation of live attenuated influenza A virus vaccine using PROTAC technology

Combining AI and Zebrafish to Accelerate Drug Discovery

Anticancer drug candidate that targets a human protein could be a pan-viral medication

Just like magic; automated solutions for NGS library preparation

Investigating the prerequisites for developing RNA-based antibiotics

New machine learning method may improve the identification of genes that cause diseases

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

Scientists create new fluorophores that could help fight cancer

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Bisphosphonates appear to improve COVID-19 exposure outcomes

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest Life Science News